Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

Study Overview
=================
Brief Summary
-----------------
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.

Detailed Description
-----------------
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.

Official Title
-----------------
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

Conditions
-----------------
Retinitis Pigmentosa

Intervention / Treatment
-----------------
* Biological: Retinal pigment epitheliums transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 and under 80 years of age, both gender, in good health. Clinical diagnosis of retinitis pigmentosa, the results of eye electrophysiological examination accord with retinitis pigmentosa. The BCVA of target eye will not be better than 20/400. The BCVA of contralateral eye is not worse than 20/400. Diopter is smaller than 8.00 D, axial 28 mm or less. Voluntary as test subjects, signed informed consent, regular follow-up will be effected according to the specified time. Exclusion Criteria: Subject with other additional retinal diseases, like diabetic or hypertensive retinopathy vascular diseases. Target eye ever have had a eye surgery; Subject with active serious diseases of the digestive system, liver kidney impairment (ALT/AST) > 1.5 or any known liver disease, creatine > 1.3 mg/dL) and/serious temic diseases, such as cardiovascular tem, respiratory tem, nervous tem, endocrine tem urogenital tem diseases, etc.), the history of malignancy; Have been ready for pregnancy during test, are lactating women; Ready to birth of men during the test; Subject with any immunodeficiency; Subject in the immunosuppressive therapy in the current; Subject with the tacrolimus or other large ring lactone class drug allergies; Participate in any clinical subjects in nearly six months; Has a history of alcohol or illicit drug abuse; Poor adherence to complete studies; Researchers believe that there may be an increased risk subjects or interfere with the clinical trials of any situation (such as when a patient is prone to mental tension, depression, mental illness, cognitive dysfunction, etc.).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: retinal pigment epitheliums transplantation<br>Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000. | Biological: Retinal pigment epitheliums transplantation<br>* Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events and serious adverse events occurred within 1 year after transplantation | The occurrence of adverse events (AE), severe adverse events (SAE), treatment-related adverse events (TEAE), and clinically significant vital signs during the study period. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of visual function | The changes of BCVA and EDTRS were observed one year after surgery. | one year |